News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MorphoSys AG Receives Two Phase 2 Milestone Payments From Janssen Biotech Inc.


9/17/2013 9:23:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today it received clinical milestone payments from Janssen Biotech, Inc. ("Janssen") following the initiation of two clinical trials. One trial initiated in asthmatic patients is studying the HuCAL antibody CNTO 3157 and a second trial initiated in patients with active rheumatoid arthritis is studying the HuCAL antibody CNTO 6785. Further financial details were not disclosed.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES